title: [Frequency of T-cell mediated rejection in new-onset diabetes after kidney transplantation].
abstract: BACKGROUND
  New-onset diabetes is one of the most common complications after kidney transplantation.
  
  
  OBJECTIVE
  The aims of the authors were to examine the frequency of new-onset diabetes mellitus in kidney transplanted patients receiving cyclosporine A (n = 95) and tacrolimus (n = 102) and to analyze the occurrence of T-cell mediated rejection in these two groups of patients.
  
  
  METHODS
  Age, laboratory results, renal function and histological findings were evaluated one year after kidney transplantation. Histological evaluation was performed according to the 2007 modification of the Banff 1997 classification.
  
  
  RESULTS
  New-onset diabetes developed in 12% of patients receiving cyclosporine A-based immunosuppression and in 24% of patients taking tacrolimus (p = 0.002). Uric acid level (p = 0.002) and the age of the recipient (p = 0.003) were significantly different in the new-onset diabetic and non-diabetic groups, while renal function showed no significant difference. Evaluation of tissue samples revealed a significant difference in T-cell mediated rejection between the new-onset diabetic and non-diabetic groups (13 vs. 8 patients; 37% vs. 6%; p = 0.001).
  
  
  CONCLUSIONS
  The results indicate an early development of the pathological effect of new-onset diabetes after kidney transplantation on the morphology of the renal allograft.
authors.affiliation: Sebészeti Klinika, Szegedi Tudományegyetem, Általános Orvostudományi Kar Szeged, Szőkefalvi-Nagy B. u. 6., 6720.
authors.forename: Bernadett
authors.initials: B
authors.lastname: Borda
authors.forename: Edit
authors.initials: E
authors.lastname: Szederkényi
authors.forename: Csaba
authors.initials: C
authors.lastname: Lengyel
authors.forename: Tamás
authors.initials: T
authors.lastname: Várkonyi
authors.forename: Zoltán
authors.initials: Z
authors.lastname: Hódi
authors.forename: Éva
authors.initials: É
authors.lastname: Kemény
authors.forename: Viktor
authors.initials: V
authors.lastname: Szabó
authors.forename: György
authors.initials: G
authors.lastname: Lázár
mesh_terms: D000328:Adult; D000368:Aged; D016572:Cyclosporine / Q000008:administration & dosage / Q000009:adverse effects*; D003920:Diabetes Mellitus / Q000453:epidemiology* / Q000209:etiology / Q000276:immunology*; D005260:Female; D006084:Graft Rejection / Q000453:epidemiology* / Q000276:immunology*; D006085:Graft Survival; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects*; D015994:Incidence; D016030:Kidney Transplantation / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D013601:T-Lymphocytes / Q000276:immunology*; D016559:Tacrolimus / Q000008:administration & dosage / Q000009:adverse effects*
chemical_list: D007166:Immunosuppressive Agents; D016572:Cyclosporine; D016559:Tacrolimus
keywords: T-cell mediated rejection; T-sejt-mediált rejectio; new-onset diabetes mellitus after transplantation; protocol biopsy; protokollbiopszia; újonnan kialakult diabetes mellitus